– Flora’s analysis division, Flora Pharma, recordsdata USPTO provisional patent software on a cannabinoid-based formulation
– Flora seeks approval to take their patent-pending, cannabinoid-based product by way of scientific trials underneath an EUA from INVIMA (Colombian FDA)
– Breakthrough analysis intends to discover a preventative software in opposition to the SARS-CoV-2 (COVID-19) virus for the patent-pending cannabinoid formulation
– If authorized, Flora’s formulation can be the primary product containing cannabinoids authorized by the Colombian authorities to be used in opposition to the SARS-CoV-2 (COVID-19) virus
MIAMI & TORONTO, February 02, 2022–(BUSINESS WIRE)–Flora Development Corp. (NASDAQ: FLGC) (“Flora” or the “Firm”), a number one all-outdoor cultivator and producer of worldwide hashish merchandise and types, introduced right this moment that the Firm is in search of approval from INVIMA, the Colombian FDA, to start analysis on their patent-pending, cannabinoid-based product, citing latest research stating the opportunity of cannabinoids to show viral inhibition.
“We’re honored to obtain the recommendation and pointers from INVIMA as we start this thrilling analysis course of. The Flora Pharma division seeks to acquire proof to assist this product’s use in opposition to SARS-CoV-2 and convey to market an efficient, cannabinoid-based product,” mentioned Luis Merchan, President and CEO of Flora Development.
This various research might be performed by way of Flora’s analysis division, Flora Pharma, with formulation going down in its GMP-certified Colombian lab. The analysis will have a look at the entire potential mechanisms of cannabinoids in stopping an infection from the SARS-CoV-2 (COVID-19) virus. This software comes on the heels of Colombia’s new laws requiring insurance coverage corporations to cowl hashish prescriptions.
“I’ve labored on numerous features of SARS-CoV-2 analysis for the final two years, with a concentrate on cannabinoid therapeutics extra broadly,” mentioned Dr. Annabelle Manalo-Morgan, scientist and head of Flora Pharma. “The intent of the research is to establish secure and efficacious cannabinoid merchandise to be used on SARS-CoV-2 thus permitting us to pursue the quickest path to market by way of a preventative immunomodulating product and to discover the opportunity of use as a therapeutic. I consider the Flora staff is finest positioned to formulate, take a look at and finally deliver to the market this type of novel product providing.”
Dr. Manalo-Morgan has spent the final 5 years researching hashish and has specialised within the formulation of cannabinoid merchandise for scientific trials. Ought to Flora’s formulation obtain INVIMA approval, this is able to be the primary product containing cannabinoids authorized by the Colombian authorities to be used in opposition to the SARS-CoV-2 (COVID-19) virus.
“At Flora Development, we consider in following the analysis, and there have been a number of promising research printed in simply the previous couple of months on the appliance of cannabinoids in sure therapies. We’re excited for our Flora Pharma researchers to construct upon this progress and generate new knowledge for the way hashish may assist customers all over the world, leveraging this pure, botanical different,” Merchan mentioned.
About Flora Development Corp.
Flora is constructing a linked, design-led collective, of plant-based wellness and life-style manufacturers, that delivers essentially the most compelling buyer experiences on this planet, one group at a time. Because the operator of one of many largest out of doors hashish cultivation services, Flora leverages pure, cost-effective cultivation practices to produce hashish derivatives to its various enterprise divisions of cosmetics, hemp textiles, and meals and beverage. Go to www.floragrowth.com or observe @floragrowthcorp on social for extra info.
Cautionary Assertion Regarding Ahead-Wanting Statements
This doc comprises forward-looking statements. As well as, sometimes, we or our representatives could make forward-looking statements orally or in writing. We base these forward-looking statements on our expectations and projections about future occasions, which we derive from the knowledge at present out there to us. Such forward-looking statements relate to future occasions or our future efficiency, together with: the scale of markets for hashish and hashish merchandise; Flora’s capability to execute on its analysis and pharmaceutical methods; the outcomes of Flora’s analysis; the collaboration with third events; and our enterprise prospects and alternatives. You possibly can establish forward-looking statements by these that aren’t historic in nature, notably those who use terminology corresponding to “could,” “ought to,” “expects,” “anticipates,” “contemplates,” “estimates,” “believes,” “plans,” “projected,” “predicts,” “potential,” or “hopes” or the adverse of those or comparable phrases. In evaluating these forward-looking statements, it’s best to think about numerous elements, together with: our capability to vary the course of the Firm; our capability to maintain tempo with new know-how and altering market wants; and the aggressive surroundings of our enterprise. These and different elements could trigger our precise outcomes to vary materially from any forward-looking assertion. Ahead-looking statements are solely predictions. The forward-looking occasions mentioned on this doc and different statements made sometimes by us or our representatives could not happen, and precise occasions and outcomes could differ materially and are topic to dangers, uncertainties and assumptions about us. We undertake no obligation to publicly replace or revise any forward-looking assertion, whether or not on account of uncertainties and assumptions, or the forward-looking occasions mentioned on this doc and different statements made sometimes by us or our representatives not occurring, besides as could also be required by relevant regulation.
View supply model on businesswire.com: https://www.businesswire.com/news/home/20220202005408/en/
+1 (858) 264-6600